28 May BellBrook Labs secures two patents for drug screening platform
Madison, Wis. – BellBrook Labs, a maker of high throughput screening tools used in drug discovery, has received two patents for Transcreener, its drug screening platform.
The patents, approved by the U.S. Patent and Trademark Office, are the second and third patents issued for Transcreener. The technology allows screening of multiple, high-value drug targets and has been used for large-scale screening in manufacturing and biotechnology companies.
The three patents cover a method used to detect certain enzymes. Additional patent applications related to Transcreener have been filed on behalf of BellBrook Labs by the law firm Quarles & Brady.
• Bellbrook Labs gets patent for assay platform
• Grants worth $800,000 help BellBrook Labs develop products
• Emerging technology companies receive significant funding
• BellBrook Labs gets major research funding